S&P 500   0.54 (+5.44%)
DOW   0.54 (+5.44%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
S&P 500   0.54 (+5.44%)
DOW   0.54 (+5.44%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
S&P 500   0.54 (+5.44%)
DOW   0.54 (+5.44%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
S&P 500   0.54 (+5.44%)
DOW   0.54 (+5.44%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
Log in

NASDAQ:FUSNFusion Pharmaceuticals Stock Price, Forecast & News

$13.13
-0.50 (-3.67 %)
(As of 08/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$13.13
Now: $13.13
$13.98
50-Day Range N/A
52-Week Range
$12.19
Now: $13.13
$19.00
Volume47,124 shs
Average Volume287,264 shs
Market Capitalization$547.05 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.43 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FUSN
CUSIPN/A
CIKN/A
Phone289-799-0891

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees37
Market Cap$547.05 million
Next Earnings DateN/A
OptionableNot Optionable
$13.13
-0.50 (-3.67 %)
(As of 08/5/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive FUSN News and Ratings via Email

Sign-up to receive the latest news and ratings for FUSN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Fusion Pharmaceuticals (NASDAQ:FUSN) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Fusion Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fusion Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Fusion Pharmaceuticals
.

What price target have analysts set for FUSN?

4 brokers have issued 12-month price objectives for Fusion Pharmaceuticals' shares. Their forecasts range from $23.00 to $25.00. On average, they expect Fusion Pharmaceuticals' share price to reach $24.33 in the next twelve months. This suggests a possible upside of 85.3% from the stock's current price.
View analysts' price targets for Fusion Pharmaceuticals
.

Has Fusion Pharmaceuticals been receiving favorable news coverage?

Press coverage about FUSN stock has trended neutral recently, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Fusion Pharmaceuticals earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future.
View the latest news about Fusion Pharmaceuticals
.

Who are some of Fusion Pharmaceuticals' key competitors?

When did Fusion Pharmaceuticals IPO?

(FUSN) raised $126 million in an IPO on Friday, June 26th 2020. The company issued 8,400,000 shares at $14.00-$16.00 per share. Morgan Stanley, Jefferies and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Fusion Pharmaceuticals' stock symbol?

Fusion Pharmaceuticals trades on the NASDAQ under the ticker symbol "FUSN."

When did the company's quiet period expire?

Fusion Pharmaceuticals' quiet period expired on Wednesday, August 5th. Fusion Pharmaceuticals had issued 12,500,000 shares in its IPO on June 26th. The total size of the offering was $212,500,000 based on an initial share price of $17.00. During the company's quiet period, insiders and underwriters that worked on the IPO were prevented from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

Who are Fusion Pharmaceuticals' major shareholders?

Fusion Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include UBS Group AG (0.01%).
View institutional ownership trends for Fusion Pharmaceuticals
.

Which major investors are buying Fusion Pharmaceuticals stock?

FUSN stock was purchased by a variety of institutional investors in the last quarter, including UBS Group AG.
View insider buying and selling activity for Fusion Pharmaceuticals
.

How do I buy shares of Fusion Pharmaceuticals?

Shares of FUSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Fusion Pharmaceuticals' stock price today?

One share of FUSN stock can currently be purchased for approximately $13.13.

How big of a company is Fusion Pharmaceuticals?

Fusion Pharmaceuticals has a market capitalization of $547.05 million. Fusion Pharmaceuticals employs 37 workers across the globe.

What is Fusion Pharmaceuticals' official website?

The official website for Fusion Pharmaceuticals is fusionpharma.com.

How can I contact Fusion Pharmaceuticals?

Fusion Pharmaceuticals' mailing address is 270 LONGWOOD ROAD SOUTH, HAMILTON A6, L8P 0A6. The company can be reached via phone at 289-799-0891 or via email at [email protected]

This page was last updated on 8/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.